Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 8
Submit an article Journal homepage
827
Views
43
CrossRef citations to date
0
Altmetric
Letters to the Editor

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified

Pier Luigi zinzaniInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, ItalyCorrespondence[email protected]
,
Cinzia PellegriniInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
,
Alessandro BroccoliInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
,
Vittorio StefoniInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
,
Letizia GandolfiInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
,
Federica QuiriniInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
,
Lisa ArgnaniInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
,
Emilio BertiUniversity of Milano-Bicocca, IRCCS Ospedale Maggiore, Milano, Italy
,
Enrico DerenziniInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
,
Stefano PileriInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
&
Michele BaccaraniInstitute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
 show all
Pages 1585-1588 | Received 29 Dec 2010, Accepted 13 Mar 2011, Published online: 19 Apr 2011

References

  • Reiser M, Josting A, Soltani M, T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 2002;43:805–811.
  • Siegert W, Agthe A, Griesser H, Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992;117:364–370.
  • Evens AM, Gartenhaus RB. Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 2004;5: 289–303.
  • Mercadal S, Briones J, Xicoy B, Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19:958–963.
  • Reimer P, Rüdiger T, Geissinger E, Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27:106–113.
  • O'Connor OA, Pro B, Pinter-Brown L, Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182–1189.
  • Piekarz R, Wright J, Frye R Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood 2009;114(Suppl. 1): Abstract 1657.
  • Zinzani PL, Baliva G, Magagnoli M, Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18:2603–2606.
  • Zinzani PL, Magagnoli M, Bendandi M, Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998;9:1351–1353.
  • Dueck G, Chua N, Prasad A, Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116:4541–4548.
  • Swerdlow SH, Campo E, Harris NL, , editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edLyon: IARC2008.
  • Cheson BD, Pfistner B, Juweid ME, Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
  • Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143–151.
  • Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.